LENZ
LENZ Therapeutics, Inc.16.70
-0.38-2.22%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '25
Q&A refines launch side-effect messaging
Q&A largely reaffirmed VIZZ's strong launch with 5,000 October scripts from 2,500 doctors, but added launch nuances like shifting sales messaging from headaches to transient redness—now leading speaker decks with before-after photos. Early prescribers skew metro optometrists (80/20 split) treating 45-65-year-old females; no pricing pushback emerged. Samples reach non-target offices via inside sales, no rep expansion yet. E-pharmacy dominated early, with discounted 3-packs. Redness fades fast. Management reiterated 2026 spend at $80M-$100M commercial plus $20M-$25M G&A. Confident tone persists; investors watch DTC ramp and refills.
Key Stats
Market Cap
522.54MP/E (TTM)
-Basic EPS (TTM)
-2.06Dividend Yield
0%Recent Filings
8-K
Discloses isolated VIZZ retinal event
LENZ Therapeutics disclosed a FAERS report of a retinal tear in a VIZZ patient with significant pre-existing retinal risks like lattice degeneration and prior tears, occurring days after starting treatment on a non-dosing day. Independent specialists deem causation uncertain amid natural incidence of ~25 per 100,000 yearly. No change to safety profile. VIZZ expands in real-world use.
8-K
VIZZ launch exceeds early targets
LENZ Therapeutics launched VIZZ eye drops for presbyopia in October 2025, securing over 2,500 unique ECP prescribers and 5,000 filled prescriptions through October, with 40% repeat prescribing. Q3 revenue hit $12.5M from licensing milestones, yet net loss widened to $16.7M amid $27.6M SG&A ramp for commercialization. Pro forma cash stands at ~$324M. Launch gains momentum fast.
10-Q
Q3 FY2025 results
LENZ Therapeutics posted $12.5M license revenue in Q3 ended September 30, 2025—its first ever—via CORXEL milestones and Théa/Lotus deals, up from zero y/y while YTD hit $17.5M. SG&A surged 325% y/y to $27.6M on 88-territory salesforce ramp for VIZZ launch post-FDA nod; R&D dropped 41% y/y to $3.8M as trials wrapped. Operating loss widened to $18.9M from $12.9M y/y, net loss to $16.7M ($0.59/share) versus $10.2M ($0.38), reconciled to 28.5M diluted shares. Cash plus marketable securities stood at $202.2M, burning $36.1M in ops YTD (FCF not disclosed); ATM raised $26.1M net. VIZZ hit pharmacies mid-Q4. Competition from Vuity generics looms.
8-K
LENZ raises $80M via stock sale
LENZ Therapeutics sold 1,748,634 shares of common stock at $45.75 per share on October 7, 2025, generating gross proceeds of approximately $80 million through its at-the-market Sales Agreement with TD Securities. This block trade to a single investor bolsters the company's cash position for ongoing operations. Funds will support general corporate purposes. No risks detailed beyond standard agreement terms.
8-K
VIZZ launches for presbyopia
LENZ Therapeutics launched VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia, on September 30, 2025. Sample distribution to eye care professionals started nationwide, with consumer shipments via ePharmacy beginning in October and broad retail availability by mid-Q4 2025. Targeting 128 million U.S. adults, VIZZ improves near vision for up to 10 hours via a pinhole effect. Launch risks include mild side effects like instillation site irritation.
IMA
ImageneBio, Inc.
6.25+0.08
KALA
KALA BIO, Inc.
0.56-0.05
KLRS
Kalaris Therapeutics, Inc.
8.66+0.16
LBRX
LB Pharmaceuticals Inc
19.82-0.04
LNSR
LENSAR, Inc.
12.06+0.54
LYRA
Lyra Therapeutics, Inc.
3.86-0.07
OPT
Opthea Limited
3.41+0.00
OTLK
Outlook Therapeutics, Inc.
2.47+0.30
RENB
Lunai Bioworks Inc.
1.42+0.00
SLNO
Soleno Therapeutics, Inc.
49.50-0.45